Abstract
Background
Recent evidence suggests that empiric prehospital administration of tenecteplase in out-of-hospital cardiac arrest is associated with decreased survival and lower rates of return of spontaneous circulation. While diagnostic uncertainty is a primary factor, operational hazards in austere environments must also be examined.
Main body of the abstract
This comment explores an underappreciated and potentially lethal operational hazard: the immediate chemical incompatibility between tenecteplase and dextrose-containing solutions. In chaotic pre-hospital settings, clinicians often rely on the cognitive heuristic of using dextrose lines to limit sodium intake, especially during cardiac emergencies. However, mixing tenecteplase with dextrose triggers instant crystallization and line occlusion. This effectively denies the patient the fibrinolytic agent while simultaneously compromising a critical intravenous access. To mitigate this risk, we propose three clinical safety barriers: physical segregation of dextrose from acute coronary syndrome kits, the mandatory implementation of a 20-mL normal saline flush before and after administration, and the use of point-of-care cognitive aids on drug packaging.
Conclusion
Addressing the complex outcomes of prehospital thrombolysis requires mitigating simple, yet catastrophic, chemical errors. Environmental design and strict operational protocols are essential to ensure the safe delivery of tenecteplase in the field.
Supplementary Information
The online version contains supplementary material available at 10.1186/s13049-026-01594-5.
Keywords: Tenecteplase, Drug Incompatibility, Patient Safety, ST-Elevation Myocardial Infarction (STEMI), Prehospital Care, Medication Errors
Background
Cowley et al. [1] recently reported decreased survival and return of spontaneous circulation (ROSC) associated with empiric prehospital tenecteplase (TNK) in out-of-hospital cardiac arrest. While diagnostic uncertainty undoubtedly plays a major role in these complex outcomes, we propose that an underappreciated operational hazard—inadvertent chemical incompatibility—might also contribute to real-world therapeutic failures in such chaotic environments.
As TNK supplants alteplase as the standard of care for pre-hospital fibrinolysis [2]—supported by the ASSENT-2 trial demonstrating equivalent mortality with superior ease of administration [3]—a dangerous safety gap has emerged.
Main text
While alteplase carries strict dilution restrictions, tenecteplase presents an immediate and severe chemical incompatibility with dextrose-containing solutions. Although the Summary of Product Characteristics (SmPC) notes this contraindication, the immediate physical consequence—precipitation and line crystallization—is often buried in technical documentation [4]. To our knowledge, no specific clinical case reports describe the operational failure (e.g., immediate line occlusion) in the field, suggesting a significant gap in reporting and awareness.
In the high-stakes environment of pre-hospital care and resuscitation, providers often operate under "System 1" thinking. A dangerous cognitive trap occurs when managing cardiac emergencies or ST-elevation myocardial infarction (STEMI) complicated by acute pulmonary edema. Clinicians frequently prioritize dextrose (e.g., D5W) as "keep-vein-open" lines to limit sodium intake. This "Sugar for the Heart" heuristic creates a lethal setup for TNK administration: contact with dextrose triggers immediate opalescence and precipitation, rendering the drug inert and potentially causing catheter occlusion or particulate embolization.
If this crystallization occurs during an active resuscitation as described in Cowley et al.’s cohort, the patient is effectively denied the fibrinolytic agent while a critical intravenous access line is simultaneously compromised.
To mitigate this risk, we propose three clinical safety barriers:
Physical Segregation: Only 0.9% normal saline or sterile water should be stocked within acute coronary syndrome-specific kits, with dextrose sequestered in metabolic or hypoglycemia kits.
Mandatory "Saline Bridge": To prevent line occlusion, clinicians must implement a strict 20-mL 0.9% normal saline flush both immediately before and after TNK administration. This volume is critical to fully clear the "dead space" of the intravenous tubing of any residual dextrose, regardless of the primary infusion running.
Point-of-Care Cognitive Aids: Bold warning labels should be affixed directly to TNK packaging (Fig. 1), and training must explicitly "un-teach" the historical use of glucose lines during cardiac emergencies when TNK is the fibrinolytic agent of choice.
Fig. 1.
Proposed Point-of-Care Safety Label for Remote Medical Kits. A cognitive aid designed to mitigate the risk of therapeutic error associated with the "Sugar for the Heart" heuristic. This label highlights the immediate chemical incompatibility of tenecteplase with dextrose solutions, promoting a "Zero-Dextrose" approach during the acute phase
Conclusions
We must ensure that environmental design and cognitive aids prevent pharmacological progress from being sabotaged by simple chemical errors. Recognizing and preventing the crystallization trap of tenecteplase is a critical step in improving the safety and efficacy of prehospital resuscitation protocols.
Supplementary Information
Acknowledgements
Generative AI was used for language editing and proofreading only. The authors take full responsibility for the content.
Abbreviations
- ROSC
Return of spontaneous circulation
- SmPC
Summary of Product Characteristics
- STEMI
ST-elevation myocardial infarction
- TNK
Tenecteplase
Authors’ contributions
TP conceptualized the manuscript and drafted the initial text. AA and GM critically reviewed and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.
Funding
The authors declare that no funding was received for this work.
Data availability
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Cowley A, Cody D, Jaquet E, et al. Prehospital thrombolysis with tenecteplase in out-of-hospital cardiac arrest: a retrospective cohort study. Scand J Trauma Resusc Emerg Med. 2025;33(1):204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Byrne R, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826. [DOI] [PubMed] [Google Scholar]
- 3.ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716–722. [DOI] [PubMed]
- 4.ASHP (American Society of Health-System Pharmacists). AHFS Drug Information 2024. Bethesda, MD.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

